Literature DB >> 8146279

Relative biological effectiveness of alpha-particle emitters in vivo at low doses.

R W Howell1, M T Azure, V R Narra, D V Rao.   

Abstract

The therapeutic potential of radionuclides that emit alpha particles, as well as their associated health hazards, have attracted considerable attention. The 224Ra daughters 212Pb and 212Bi, by virtue of their radiation properties which involve emission of alpha and beta particles in their decay to stable 208Pb, have been proposed as candidates for radioimmunotherapy. Using mouse testes as the experimental model and testicular spermhead survival as the biological end point, the present work examines the radiotoxicity of 212Pb and its daughters. When 212Pb, in equilibrium with its daughters 212Bi, 212Po and 208Tl, was administered directly into the testis, the dose required to achieve 37% survival (D37) was 0.143 +/- 0.014 Gy and the corresponding RBE of the mixed radiation field was 4.7 when compared to the D37 for acute external 120 kVp X rays. This datum, in conjunction with our earlier results for 210Po, was used to obtain an RBE-LET relationship for alpha particles emitted by tissue-incorporated radionuclides: RBE alpha = 4.8 - 6.1 x 10(-2) LET + 1.0 x 10(-3) LET2. Similarly, the dependence of RBE on alpha-particle energy E alpha was given by RBE alpha = 22 E(-0.73) alpha. These relationships, based on in vivo experimental data, may be valuable in predicting biological effects of alpha-particle emitters.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8146279      PMCID: PMC3321060     

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  35 in total

1.  Chromosome damage in liver cells from low dose rate alpha, beta, and gamma irradiation: derivation of RBE.

Authors:  A L Brooks
Journal:  Science       Date:  1975-12-12       Impact factor: 47.728

2.  Microdosimetry of internal sources.

Authors:  W C Roesch
Journal:  Radiat Res       Date:  1977-06       Impact factor: 2.841

3.  In-vivo radiotoxicity of DNA-incorporated 125I compared with that of densely ionising alpha-particles.

Authors:  D V Rao; V R Narra; R W Howell; G F Govelitz; K S Sastry
Journal:  Lancet       Date:  1989-09-16       Impact factor: 79.321

4.  Cell survival following multiple-track alpha particle irradiation.

Authors:  E L Lloyd; M A Gemmell; C B Henning; D S Gemmell; B J Zabransky
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1979-01

5.  "Biological dosimetry" of radionuclides and radiation hazards.

Authors:  M E Gaulden
Journal:  J Nucl Med       Date:  1983-02       Impact factor: 10.057

6.  Radiation dose and biological effects to mouse testis from sodium 32P-phosphate.

Authors:  T A Mian; H J Glenn; T P Haynie; M L Meistrich
Journal:  Health Phys       Date:  1982-05       Impact factor: 1.316

7.  Biological consequence of nuclear versus cytoplasmic decays of 125I: cysteamine as a radioprotector against Auger cascades in vivo.

Authors:  D V Rao; V R Narra; R W Howell; K S Sastry
Journal:  Radiat Res       Date:  1990-11       Impact factor: 2.841

8.  Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. IV. Biophysical interpretation.

Authors:  D T Goodhead; R J Munson; J Thacker; R Cox
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1980-02

9.  Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design.

Authors:  V R Narra; R W Howell; R S Harapanhalli; K S Sastry; D V Rao
Journal:  J Nucl Med       Date:  1992-12       Impact factor: 10.057

10.  Reduction in sperm levels after testicular irradiation of the mouse: a comparison with man.

Authors:  M L Meistrich; R C Samuels
Journal:  Radiat Res       Date:  1985-04       Impact factor: 2.841

View more
  11 in total

1.  Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.

Authors:  Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Martin W Brechbiel
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Biological effect of lead-212 localized in the nucleus of mammalian cells: role of recoil energy in the radiotoxicity of internal alpha-particle emitters.

Authors:  M T Azure; R D Archer; K S Sastry; D V Rao; R W Howell
Journal:  Radiat Res       Date:  1994-11       Impact factor: 2.841

3.  Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo.

Authors:  R W Howell; S M Goddu; V R Narra; D R Fisher; R E Schenter; D V Rao
Journal:  Radiat Res       Date:  1997-03       Impact factor: 2.841

4.  Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.

Authors:  Kwon Yong; Martin Brechbiel
Journal:  AIMS Med Sci       Date:  2015-08-18

5.  Patient exposures and consequent risks from nuclear medicine procedures.

Authors:  Roger W Howell
Journal:  Health Phys       Date:  2011-03       Impact factor: 1.316

6.  Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.

Authors:  Jostein Dahle; Thora J Jonasdottir; Helen Heyerdahl; Jahn M Nesland; Jørgen Borrebaek; Anne Kristine Hjelmerud; Roy H Larsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

7.  Methodology for labeling proteins and peptides with lead-212 (212Pb).

Authors:  Kwamena E Baidoo; Diane E Milenic; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2013-04-17       Impact factor: 2.408

8.  Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model.

Authors:  Megan Minnix; Vikram Adhikarla; Enrico Caserta; Erasmus Poku; Russell Rockne; John E Shively; Flavia Pichiorri
Journal:  J Nucl Med       Date:  2020-10-30       Impact factor: 10.057

9.  Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223.

Authors:  Didier A Rajon; Brian S Canter; Calvin N Leung; Tom A Bäck; J Christopher Fritton; Edouard I Azzam; Roger W Howell
Journal:  Int J Radiat Biol       Date:  2021-07-26       Impact factor: 3.352

10.  Selectivity Conversion of Protease Inhibitory Antibodies.

Authors:  Tyler Lopez; Aaron Ramirez; Chris Benitez; Zahid Mustafa; Henry Pham; Ramon Sanchez; Xin Ge
Journal:  Antib Ther       Date:  2018-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.